| Identification | Back Directory | [Name]
Pyrazolo[1,5-a]pyrimidine-3-acetamide,N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethyl- | [CAS]
958233-07-3 | [Synonyms]
Pyrazolo[1,5-a]pyrimidine-3-acetamide,N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethyl-
N,N-diethyl-2-[2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide | [Molecular Formula]
C22H27FN4O2 | [MOL File]
958233-07-3.mol | [Molecular Weight]
398.47 |
| Chemical Properties | Back Directory | [Melting point ]
160-163 °C | [density ]
1.18±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 41.67 mg/mL (104.57 mM) | [form ]
Solid | [pka]
1.08±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
DPA-714 is a high affinity translocator protein (TSPO) ligand (Ki=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. 18FDPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model[1][2]. | [in vivo]
[18F]DPA-714 binding significantly increases in vivo as a result of AD‐like pathology and age in APPswe×PS1Δe9 mice. | [References]
[1] James ML, et al. DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med. 2008 May;49(5):814-22. DOI:10.2967/jnumed.107.046151
[2] Harhausen D, et al. Specific imaging of inflammation with the 18 kDa translocator protein ligand DPA-714 in animal models of epilepsy and stroke. PLoS One. 2013 Aug 2;8(8):e69529. DOI:10.1371/journal.pone.0069529 |
|
|